We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how and talented people.
Everyone at GSK focuses on three priorities: Innovation, Performance, Trust
We have ~15k employees living and working in communities across the US.
Where we live matters to our health. That's why we want to build healthy communities.
Information regarding our codes of conduct, public policies, and other reporting information.
Many of our brands, such as Sensodyne, Aquafresh and Nicorette are familiar around the world.
Our pharmaceuticals business discovers, develops and makes medicines to treat a broad range of the world's most common acute and chronic diseases.
Our vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across over 150 countries.
ViiV Healthcare is an independent, global specialist HIV company dedicated to delivering innovative new options for the care and treatment of people living with HIV/AIDS.
Stiefel has a long history of excellence in dermatology and is research focused on acne, psoriasis, eczema, atopic dermatitis and superficial skin infections.
Search for job opportunities within GSK.
Find out what career opportunities there could be for you at GSK.
We offer many opportunities for people at various stages of their careers.
Discovering and developing new products is a long, expensive and uncertain process that requires us to be highly selective.
Find out about our clinical trials process, how we work with doctors and volunteers.
We have major research centres in the UK, USA, Europe and China. Contact details for these and other R&D centres is provided within this section.
We are committed to reporting the results of clinical research that evaluates our medicines and vaccines.
We have the opportunity to improve the health and well-being of people around the world.
Our values underpin everything we do – from ensuring rigorous safety standards in the development and manufacture of new medicines to interacting ethically with healthcare professionals, patient groups and political stakeholders.
We aim to create a safe and inclusive workplace where everyone at GSK can feel able and inspired to realize their potential and help us meet global health challenges.
We aim to reduce environmental impacts across our value chain while extending access to our products for the people who need them.
Read more - GSK announces Board changes
Read more - ViiV Healthcare announces positive results from first phase III studies of two-drug HIV treatment regimen
Read more - ViiV Healthcare Announces CHMP positive opinion to lower the age and weight limit for Tivicay® (dolutegravir) in children and adolescents living with HIV in Europe
Read more - GSK submits regulatory application in Japan for belimumab in systemic lupus erythematosus
Read more - GSK opens new global vaccines R&D center in Rockville, MD, USA
Read more - Relvar® Ellipta® 100/25 mcg gains approval in Japan for use in patients with COPD
Read more - GSK files EU regulatory submission for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD
Read more - GSK announces EU regulatory submission of candidate vaccine for prevention of shingles - Follows regulatory submissions in US and Canada
Read more - GSK starts phase III programme with daprodustat for anaemia associated with chronic kidney disease
Read more - GSK announces phase lll study of mepolizumab meets co-primary endpoints and all secondary endpoints in patients with eosinophilic granulomatosis with polyangiitis